Samsky, M., Dunning, A., Schulte, P., DeVore, A., Mentz, R., Patel, C., … Hernandez, A. (2015). Elevated Total Bilirubin on Admission is a Marker of Worse 30- and 180-Day Outcomes for Patients With Acute HF: Insights From ASCEND-HF. In Journal of Cardiac Failure (Vol. 21, pp. S120–S121). Elsevier BV. https://doi.org/10.1016/j.cardfail.2015.06.346

Samsky, Marc, Allison Dunning, Phillip Schulte, Adam DeVore, Robert Mentz, Chetan Patel, Randall Starling, et al. “Elevated Total Bilirubin on Admission is a Marker of Worse 30- and 180-Day Outcomes for Patients With Acute HF: Insights From ASCEND-HF.” In Journal of Cardiac Failure, 21:S120–21. Elsevier BV, 2015. https://doi.org/10.1016/j.cardfail.2015.06.346.

Samsky M, Dunning A, Schulte P, DeVore A, Mentz R, Patel C, et al. Elevated Total Bilirubin on Admission is a Marker of Worse 30- and 180-Day Outcomes for Patients With Acute HF: Insights From ASCEND-HF. In: Journal of Cardiac Failure. Elsevier BV; 2015. p. S120–1.

Samsky, Marc, et al. “Elevated Total Bilirubin on Admission is a Marker of Worse 30- and 180-Day Outcomes for Patients With Acute HF: Insights From ASCEND-HF.” Journal of Cardiac Failure, vol. 21, no. 8, Elsevier BV, 2015, pp. S120–21. Crossref, doi:10.1016/j.cardfail.2015.06.346.

Samsky M, Dunning A, Schulte P, DeVore A, Mentz R, Patel C, Starling R, Teerlink J, Tang W, Armstrong P, Ezekowitz J, Metra M, Voors A, McMurray J, Butler J, O’Connor C, Hernandez A. Elevated Total Bilirubin on Admission is a Marker of Worse 30- and 180-Day Outcomes for Patients With Acute HF: Insights From ASCEND-HF. Journal of Cardiac Failure. Elsevier BV; 2015. p. S120–S121.